Citron Research to Discuss Valeant Pharma (VRX) at 12:30PM on Bloomberg

Valeant Pharma (VRX) on Watch Ahead of Citron Interview

October 22, 2015 12:17 PM EDT

Traders are closing watching Valeant Pharma (NYSE: VRX) with the Citron Research interview forthcoming (12:30Pm ET). Shares could see a 'sell the rumor... buy the news' reaction if nothing new is disclosed. Shares are currently down 16.7% to $98.61.

http://www.bloomberg.com/live

... More

Valeant Pharma (VRX) Continues Free Fall; Down 20%

October 22, 2015 11:26 AM EDT

Valeant Pharma (NYSE: VRX) continues lower into Citron Research interview. Now down 20%

... More

Valeant Pharma (VRX) Resumes Free-Fall; Down 15%

October 22, 2015 9:44 AM EDT

Valeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.

Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.

... More

Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating

October 22, 2015 9:37 AM EDT

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.

Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More

Pre-Open Stock Movers 10/22: (OCLR) (PFPT) (TXN) (MCD) Higher; (RLYP) (CYH) (APOL) (VRX) Lower (more...)

October 22, 2015 9:30 AM EDT

Relypsa (NASDAQ: RLYP) 31.6% LOWER; reversing earlier gains following FDA approval of Veltassa. Declines appear related to concerns about the drug's label. Analysts at Morgan Stanley described the label as "highly restrictive" and said it will probably limit demand.

Community Health Systems (NYSE: CYH) 23.3% LOWER; announced preliminary financial and operating results for the three... More

Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch

October 22, 2015 7:26 AM EDT

BofA/Merrill Lynch maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $290. Analyst Sumant S. Kulkarni said he continues to monitor concerns related to improper pricing and alleged irregularities in financial reporting, but he believes Valeant presents an "enhanced... More

S&P 500 ends at highest in two months; Alphabet up after hours

October 22, 2015 7:00 AM EDT

By Caroline Valetkevitch

(Reuters) - The S&P 500 closed at its highest in two months on Thursday as stronger-than-expected earnings from several top companies, including McDonald's, relieved investors' concerns about the profit outlook.

Buying accelerated after the close, with broad gains in tech and other companies that reported results, including Alphabet (NASDAQ: GOOGL), up 9.6 percent at $746.78, and Microsoft (NASDAQ: MSFT), up 7.2 percent at $51.50. Amazon (NASDAQ: AMZN) rose 10.6 percent to $623.75 after it posted results.

Nasdaq 100 futures jumped after the close... More

BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy Structure

October 22, 2015 7:00 AM EDT

BMO Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform with a price target of $141.00, saying they cannot defend the specialty pharmacy structure.

Analyst Alex Arfaei commented, "Based on our understanding, ~10% of Valeants revenues come from specialty pharmacies. While other companies also use specialty pharmacies, the structure of Valeants network seems different. In... More